A start-up company led by top international researchers in gut microbiology and immunity
Hefei IBIOME Biotechnology Co., Ltd. is a biotechnology company focusing on the innovative research and development of human gut microbiota, and a start-up company led by top international researchers in gut microbiology and immunity. The core R&D team consists of scientists from top international universities such as Yale University, Harvard Medical School, and University of Science and Technology of China.
The company's core business is the development of intestinal bacteria drugs, and the immunotherapy of human intestinal microorganisms. Develop clinical treatment solutions including metabolic diseases, anti-tumor, inflammatory bowel disease, autoimmune diseases, etc., marking the development of the largest domestic and international immunomodulatory strains development enterprise.
|
|
Experimental Area - Molecular Laboratory
|
|
Experimental area - process room
|
|
Experimental area - bacterial isolation room
|
|
Experimental Area - Molecular Laboratory
|
|
Experimental Area - Molecular Laboratory
|
|
Experimental Area - Microbial Library
|
|
Recreation area
|
|
Experimental area - intercellular
|
|
Experimental area - clean area
|
|
Experimental area - clean area
|
|
Experimental area - process room
|
|
Experimental area - process room
|
|
Experimental area - bacterial isolation room
|
|
Open office area
|
|
Reception area
|
|
Recreation area
|
|
Park environment
|
|
Park environment
Working environment
|
|
Professional R&D team
The company's core R&D team is composed of many scientists from top international universities such as Yale University, Harvard Medical School, University of Science and Technology of China, Chinese Academy of Sciences, etc., and has a solid working foundation in the research of intestinal microbes, host immunity, and intestinal microbe-related diseases. , research results have been published in top international journals for many times.
Cell (2021), Nature Reviews Gastroenterology & Hepatology, (2021), PNAS (2021), Nature Immunology (2019), Nature (2017a, 2017b), Science (2015), Nat Comm (2015).
|
|
Yale University
|
|
Harvard University
|
|
University of Science and Technology of China
|
|
Chinese Academy of Sciences
Richard Flavell, PhD
—
Professor, Yale University
Immunology
IBD
Immune-Microbiome
Weng Jianping, Ph.D.
—
Chinese Academy of Sciences Clinical
Hospital Dean
Endocrine metabolism
disease
Eran Elinav, MD, PhD
—
Professor, Weizmannx Institute
Microbiome
Personized nutrition
Microbiota
Zhao Shen Li, Ph.D.
—
Chinese Academy of Engineering
academician
Changhai Hospital Digestion
Director of Internal Medicine
Noah Palm, PhD
—
Assistant Professor,
Yale University
Microbial metabolites
IgA sequencing
Hong Zhang, Ph.D.
—
Peking University First Hospital Kidney
Deputy Director of Internal Medicine
IgA nephropathy
Strong consultant team
Mechanisms of Gut Microbiota Interaction with the Immune and Nervous Systems
Disease Therapy and Intervention
Cell , 2023, 2021
PANS , 2024
Sci Adv, 2023
Cell Research, 2023
Cell , In Revision
Cell Reports, 2024
Mowement Disorder, 2020
Nature, 2017a
Science, 2015
Immunity, 2024
Nature Cell Biology, 2024
Cell Host Microbe, 2024
Cell Reports, 2024
Cell Reports, 2022
Mowement Disorder, 2020
Nature Biomedical Engineering, 2022
Red , coauthor ; Blue , (co)first or corresponding author
Address: Building 5, Phase 5, Intelligent Technology Park,
Economic and Technological Development Zone, Hefei, Anhui, China.
Tel: 0551-63813386
Email: hr@ibiome.com.cn